Engineered cells expressing true epitope accepting MHC extracellular domains

By displaying non-covalently linked HLA heterodimers on the surface of yeast cells, the HLA characterization and stability problems were solved, and an efficient method for rapid identification of MHC restriction antigen peptides and developing HLA neoantigen immune molecules was achieved, thereby improving tumor targets Efficiency towards drug development.

CN118956629APending Publication Date: 2024-11-15JWE (BEIJING) SCIENCE TECHNOLOGY INC +1
View PDF 10 Cites 0 Cited by

Patent Information

Application Number
CN202411000616.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-24
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

The prior art is difficult to effectively characterize and display MHC-restricted antigens in human leukocyte antigen molecules (HLAs), especially in the development of tumor-associated antigen-targeted drugs, with expression and stability challenges.

Method used

By displaying non-covalently linked MHC class I or class II heterodimers on the surface of yeast cells, using specific nucleic acid sequences and signal peptides to ensure the correct folding and peptide acceptance function of HLA molecules, the EXTREME system is developed for rapid identification of MHCs Restrictive antigenic peptide.

Benefits of technology

Achieve efficient and accurate development of HLA neoantigen immune molecular drug precursors, such as HLA neoantigen peptides and their derived vaccines and T cell receptors, improving the efficiency of high-throughput peptide loading affinity experiments in vitro and through conformation-specific antibodies The activity and stability of the natural epitope-receptive HLA molecules that are correctly folded on the surface of yeast cells was verified.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004962310430000281
    Figure BDA0004962310430000281
  • Figure BDA0004962310430000291
    Figure BDA0004962310430000291
  • Figure BDA0004962310430000301
    Figure BDA0004962310430000301
Patent Text Reader

Abstract

The present application provides an engineered cell expressing a true epitope accepting MHC extracellular domain comprising a human leukocyte antigen molecule (HLA molecule) wherein the HLA molecule comprises a first chain and a second chain wherein the first chain of the HLA molecule is selected from a heavy chain of HLA class I or an alpha chain of HLA class II and the second chain of the HLA molecule is selected from a light chain of HLA class I or a beta chain of HLA class II, the first chain and the second chain of the HLA molecule are non-covalently connected to form the HLA molecule with a natural HLA molecule function. The engineered cell provided by the invention can be used for rapidly developing and identifying the MHC restricted antigen peptide, and can efficiently and accurately develop and identify the HLA new antigen immune molecule prodrug.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application belongs to the field of immunotechnology, and specifically relates to displaying an epitope-receptive major histocompatibility complex in a natural conformation by yeast surface display technology. Background Art

[0002] More than 99% of tumor-associated antigens (some are special tumor-specific antigens, defined as neoantigens) are presented by the major histocompatibility complex (MHC), making them targetable drug targets. However, compared with anti-tumor drugs targeting classic immune markers (such as PD1 / PDL1, CD20 and CD19) or cytokines (such as TNF, HER2 and VEGF), immunotherapies targeting MHC neoantigen targets are not common in the market. Among the many factors that limit the development of MHC neoantigen-targeted drugs, the challenge of exploring the characterization of MHC-restricted antigens is the first.

[0003] Conventional human MHC includes human leukocyte antigen molecules class I and class II, referred to as HLA-I and HLA-II, respectively. The typical HLA-I allele protein consists of an α heavy chain and a β light chain, the expression of which depends on the HLA allele carried by the individual HLA haplotype (i.e., HLA-A, HLA-B, or HLA-C), and a β light chain shared by all HLA-I heterodimers, i.e., β2-microglobulin (β2m). The typical HLA-II allele protein consists of an α chain and a β chain of almost equal length, and the expression of these two chains depends on the HLA allele carried by the individual HLA haplotype (i.e., HLA-DR, HLA-DQ, or HLA-DP). The HLA-I proteins expressed by most cell types provide antigenic peptides for CD8+ T cell recognition, while the HLA-II proteins expressed primarily by professional antigen presenting cells (APCs) provide antigenic peptides for CD4+ T cell recognition. Thus, HLA-I molecules, but not HLA-II molecules, are frequently detected on the surface of tumor cells, especially in late stages of cancer before their downregulation.

[0004] Mass spectrometry has been used in the field of HLA ligandome discovery for decades. Not only has our knowledge of peptide-HLA (pHLA) binding increased, mass spectrometry and related bioinformatics techniques have also greatly improved, allowing thousands of HLA-associated peptides to be isolated and analyzed in a matter of weeks or even days. Despite the large amount of mass spectrometry data available, complementary pHLA characterization analytical methods are still needed for peptide affinity identification. The yeast display system has proven to be a cutting-edge method for pHLA affinity analysis due to its eukaryotic origin mimicking mammalian cells, its ease of cloning similar to prokaryotic cell systems, its high-throughput convenience for high-throughput cell analysis, and more importantly, its ability to express and display HLA heterodimers and its system compatibility and tolerance.

[0005] To display HLA-I allele proteins on the surface of yeast cells, a given α chain and β2m are usually covalently linked to each other to ensure the highest chance of heavy chain / light chain dimerization. In addition, specific peptides are also covalently linked to the α chain or β2m, facilitating the yeast to display single-chain pHLA-I trimers. Previously, β2m-specific antibodies have successfully detected β2m on the surface of yeast, indicating the presence of trimers. It remains unclear whether these trimers are correctly folded and whether HLA-I heterodimers are still stably expressed and accept peptides once the peptide is missing. Solving these issues is key to the important role that epitope-receptive MHC displayed by yeast can play in the development of medicinal new antigen epitopes and their corresponding vaccines and immunotherapies. Summary of the invention

[0006] The present application provides engineered cells displaying non-covalently dimerized MHC class I or class II heterodimers, nucleic acids encoding MHC class I or II α and β chains, and uses and preparation methods of engineered cells. These engineered cells can be used to characterize MHC restricted antigens.

[0007] Specifically, this application involves the following contents:

[0008] 1. A cell comprising a human leukocyte antigen molecule (HLA molecule), wherein the HLA molecule comprises a first chain and a second chain, wherein:

[0009] The first chain of the HLA molecule is selected from the HLA-I class heavy chain or the HLA-II class α chain,

[0010] The second chain of the HLA molecule is selected from the light chain of HLA-I class or the beta chain of HLA-II class,

[0011] The first chain and the second chain of the HLA molecule are non-covalently linked to form an HLA molecule having the function of a natural HLA molecule.

[0012] 2. The cell according to item 1, wherein the cell is a yeast cell.

[0013] 3. A cell according to item 1 or 2, wherein the first chain of the HLA molecule is linked to a molecule on the surface of the cell and binds to the surface of the cell.

[0014] 4. A cell according to item 3, wherein the molecule is a protein.

[0015] 5. A cell according to item 4, wherein the protein is endogenous to the cell.

[0016] 6. The cell according to item 4, wherein the protein is Aga2p, a-lectin, α-lectin, flocculin, Cwp1p, Cwp2p or Tip1p.

[0017] 7. The cell according to item 4, wherein the protein is Aga2p.

[0018] 8. The cell according to item 7, wherein the amino acid sequence of Aga2p is as shown in SEQ ID NO: 1.

[0019] 9. The cell according to any one of items 1 to 8, wherein the first chain and the second chain of the HLA molecule form a trimer with the peptide fragment.

[0020] 10. The cell according to any one of items 1 to 9, wherein the first chain and the second chain of the HLA molecule are expressed by the cell via two expression cassettes, respectively, and are bound to the cell surface.

[0021] 11. The cell according to any one of items 1 to 10, wherein the first chain and the second chain of the HLA molecule are expressed in two directions respectively through two different promoters and bound to the cell surface, and preferably the signal peptide that promotes the expression of the first chain and the second chain of the HLA molecule is SPP SP or AGA2 SP, and further preferably the sequence of the SPP SP is as shown in SEQ ID NO: 2, and the sequence of the AGA2 SP is as shown in SEQ ID NO: 3.

[0022] 12. The cell according to item 11, wherein the two promoters are GAL10 and GAL1, respectively.

[0023] 13. The cell according to item 12, wherein the first chain is expressed on the cell surface via GAL10 and the second chain is expressed on the cell surface via GAL1.

[0024] 14. The cell according to any one of items 10 to 13, wherein the expression cassette for expressing the first chain and / or the second chain further comprises a signal peptide, preferably the signal peptide is SPP SP or AGA2 SP, further preferably the sequence of the SPP SP is as shown in SEQ ID NO: 2, and the sequence of the AGA2 SP is as shown in SEQ ID NO: 3.

[0025] 15. The cell according to any one of items 1 to 14, wherein

[0026] The first chain is encoded by HLA-A*02:01 or HLA-A*03:01 or HLA-A*11:01 or HLA-A*24:02 or HLA-A*68:02 or other alleles of HLA-A family, and the second chain is β2m; or

[0027] The first chain is encoded by HLA-B*07:02 or HLA-B*08:01 or HLA-B*27:05 or HLA-B*35:01 or HLA-B*40:01 or HLA-B*52:01 or other alleles of HLA-B family, and the second chain is β2m; or

[0028] The first chain is encoded by HLA-C*01:02 or HLA-C*03:03 or HLA-C*12:03 or other alleles of the HLA-C family, and the second chain is β2m.

[0029] 16. A cell according to any one of item 15, wherein the first chain is selected from any one of the amino acid sequences shown in SEQ ID NO:4-13 or has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity with the amino acid sequence shown in SEQ ID NO:4-13; or the second chain is the amino acid sequence shown in SEQ ID NO:14 or has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity with the amino acid sequence shown in SEQ ID NO:14.

[0030] 17. The cell according to any one of items 1 to 14, wherein

[0031] The first chain is encoded by HLA-DRA*01 or other alleles of the HLA-DRA family, and the second chain is encoded by HLA-DRB1*01 or HLA-DRB1*04 or HLA-DRB1*15 or other alleles of the HLA-DRB family; or

[0032] The first chain is encoded by HLA-DQA1*01 or other alleles of the HLA-DQA1 family, and the second chain is encoded by HLA-DQB1*06 or other alleles of the HLA-DQB1 family; or

[0033] The first chain is encoded by HLA-DPA1*01:03 or an HLA-DPA1 family allele, and the second chain is encoded by HLA-DPB1*04:01 or an HLA-DPB1 family allele.

[0034] 18. A cell according to claim 17, wherein the first chain is selected from any one of the amino acid sequences shown in SEQ ID NOs: 17 and 21 or has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity with the amino acid sequences shown in SEQ ID NOs: 17 and 21; or the second chain is selected from any one of the amino acid sequences shown in SEQ ID NOs: 18-20 or 22 or has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity with the amino acid sequences shown in SEQ ID NOs: 18-20 or 22.

[0035] 19. A nucleic acid encoding a human leukocyte antigen molecule (HLA molecule), wherein the HLA molecule comprises a first chain and a second chain,

[0036] The first chain of the HLA molecule is selected from the HLA-I class heavy chain or the HLA-II class α chain,

[0037] The second chain of the HLA molecule is selected from the light chain of HLA-I class or the beta chain of HLA-II class,

[0038] The first chain and the second chain of the HLA molecule are non-covalently linked to form an HLA molecule having the function of a natural HLA molecule.

[0039] 20. The nucleic acid according to item 19, comprising two independent expression cassettes for expressing the first chain and the second chain of the HLA molecule, respectively.

[0040] 21. The nucleic acid according to item 20, wherein the expression cassette for expressing the first chain comprises a GAL10 promoter, and the expression cassette for expressing the second chain comprises a GAL1 promoter, preferably the two expression cassettes respectively comprise a nucleic acid sequence for expressing a signal peptide, preferably the signal peptide is SPP SP or AGA2 SP, further preferably the sequence of the SPP SP is as shown in SEQ ID NO: 2, and the sequence of the AGA2 SP is as shown in SEQ ID NO: 3.

[0041] 22. The nucleic acid according to any one of Items 19 to 21, wherein the human leukocyte antigen molecule encoded by the nucleic acid is the human leukocyte antigen molecule involved in any one of Items 1 to 18.

[0042] 23. A method for preparing a human leukocyte antigen molecule (HLA molecule), the method comprising:

[0043] A cell transformed with the nucleic acid of any one of items 19 to 21, and

[0044] The cells are cultured under conditions where the human leukocyte antigen molecules (HLA molecules) mentioned in any one of items 1 to 18 are expressed.

[0045] 24. A method according to item 23, wherein the cell is a yeast cell.

[0046] 25. A method for identifying HLA neoantigen peptides and vaccines derived therefrom, comprising using the human leukocyte antigen molecule involved in any one of items 1 to 18 to recognize and / or bind to the HLA neoantigen peptides.

[0047] 26. A method for identifying HLA neoantigen receptors, comprising

[0048] Using the human leukocyte antigen molecule according to any one of items 1 to 18 to recognize and / or bind to HLA neoantigen peptides; and

[0049] The HLA-peptide trimer formed by the human leukocyte antigen molecule involved in any one of items 1 to 18 and the HLA neoantigen peptide is used to recognize and / or bind to the T cell receptor (TCR) or TCR analog or TCR derivative.

[0050] Effects of the Invention

[0051] The present application provides an innovative system (EXTREME system) for expressing true epitope-receptive MHC extracellular domains (Expressing TrulyEpitope-receptive MHC Ectodomains) for rapid development and identification of MHC-restricted antigenic peptides. Furthermore, EXTREME can efficiently and accurately develop and identify HLA neoantigen immune molecule drug precursors, such as HLA neoantigen peptides and their derived vaccines and HLA neoantigen receptors including T cell receptors (TCR) and their derived protein molecules and TCR analogs (TCRL), etc.

[0052] Compared to other MHC expression systems, the EXTREME system exhibits a number of advantages in providing an orthogonal means to validate mass spectrometry identifications and even to quantify peptide MHC binding without the need for mass spectrometry analysis. First, EXTREME is able to express a single HLA-I or HLA-II allele protein in each cell line, which would eliminate the uncertainty that a given peptide under study may bind to multiple HLAs expressed by tumor-derived primary cells or cell lines. Second, EXTREME inherits some of the advantages of yeast display, for example, as the only available eukaryotic single-cell protein display system, yeast efficiently expresses HLA proteins with necessary post-translational modifications and allows peptide binding analysis on the cell surface. Third, EXTREME not only displays the peptide-linked form of MHC as a trimeric complex, but also successfully displays the peptide-free form (i.e., epitope-receptive form) of MHC as a heterodimer. Most importantly, only when the non-covalent form of MHC is used in the EXTREME system can MHC proteins be detected using conformation-specific anti-HLA steric epitope antibodies. These anti-HLA antibodies have been widely used in mass spectrometry studies, therefore, their staining of yeast from the EXTREME system demonstrated the activity of properly folded native epitope-receptive HLA molecules on the yeast cell surface and indicated their peptide-receptive function and stability. Last but not least, EXTREME expresses single HLA allele proteins within two days, which maximizes the high efficiency required for in vitro high-throughput peptide loading affinity experiments. BRIEF DESCRIPTION OF THE DRAWINGS

[0053] Figure 1 : Yeast strains displaying various single-chain trimer constructs were indirectly stained to detect (left) HA tags at the C-terminus of Aga2 protein, (center) β2m, or (right) conformationally active HLA-I heterodimers. As shown, single-chain trimers containing peptides, β2m, and HLA-I heavy chains were displayed at the N-terminus of Aga2 protein. Background control represents the background of secondary antibody staining alone. Flow cytometry histograms counted cells with different fluorescence intensities.

[0054] Figure 2 : Yeast strains displaying various single-chain trimer constructs were indirectly stained to detect (left) HA tags at the C-terminus of Aga2 protein, (center) β2m, or (right) conformationally active HLA-I heterodimers. As shown, single-chain trimers containing peptides, β2m, and HLA-I heavy chains were displayed at the C-terminus of Aga2 protein. Background control represents the background of secondary antibody staining alone. Flow cytometry histograms counted cells with different fluorescence intensities.

[0055] Figure 3: Yeast strains displaying various peptide-linked HLA-I non-covalent heterodimer constructs were indirectly stained to detect (left) the HA tag at the C-terminus of the Aga2 protein, (center) β2m, or (right) conformationally active HLA-I heterodimers. The independently expressed heavy and light chains, the peptide / heavy chain fusions to the Aga2 protein, and the signal peptide used in each construct are indicated. Background control represents the background of secondary antibody staining alone. Flow cytometry histograms count cells with different fluorescence intensities.

[0056] Figure 4 : Yeast strains displaying various peptide-free (epitope-receptive) HLA-I non-covalent heterodimer constructs were indirectly stained to detect (left) the HA tag at the C-terminus of the Aga2 protein, (center) β2m, or (right) conformationally active HLA-I heterodimers. The heavy and light chains expressed, the fusion mode of the heavy chain to the Aga2 protein, and the signal peptide used in each construct are indicated. The background control represents the background of the secondary antibody staining alone. Flow cytometry histograms count cells with different fluorescence intensities.

[0057] Figure 5 : Yeast strains secreting (but not displaying) peptide-linked HLA-I non-covalent heterodimer constructs or displaying various alleles of epitope-accepting HLA-I non-covalent heterodimer constructs were indirectly stained to detect (left) β2m or (right) conformationally active HLA-I heterodimers. The heavy and light chains expressed, respectively, and the fusion (or not) of various alleles of HLA-I heavy chains to Aga2 protein are indicated in the figure. Flow cytometry histograms count cells with different fluorescence intensities.

[0058] Figure 6 : Yeast strains displaying various alleles of epitope-receptive HLA-I non-covalent heterodimer constructs were indirectly stained to detect (left) β2m or (right) conformationally active HLA-I heterodimers. The heavy and light chains expressed, respectively, and the fusion modes of various alleles of HLA-I heavy chain with Aga2 protein are indicated in the figure. Background control represents the background of only dichromatin staining. Flow cytometry histograms count cell counts with different fluorescence intensities. Fluorescence channel FL1 was selected for detecting antibodies specific for HLA-I conformational spatial epitopes (FL4 was selected for other figures).

[0059] Figure 7: Yeast strains secreting (but not displaying) HLA-II non-covalent heterodimer constructs or displaying various alleles of epitope-accepting HLA-II non-covalent heterodimer constructs were indirectly stained to detect conformationally active HLA-II heterodimers. The independently expressed α and β chains of HLA-II are indicated in the figure, and the fusion (or non-fusion) of HLA-II polypeptide chains with Aga2 protein. Flow cytometry histograms were used to count cells with different fluorescence intensities. DETAILED DESCRIPTION

[0060] The present application is further described below in conjunction with examples. It should be understood that the examples are only used to further describe and illustrate the present application and are not used to limit the present application.

[0061] Unless otherwise defined, the technical and scientific terms in this specification have the same meaning as those generally understood by those skilled in the art. Although similar or identical methods and materials as described herein may be used in experiments or practical applications, materials and methods are described herein below. In the event of a conflict, the present specification including the definitions therein shall prevail. In addition, materials, methods and examples are provided for illustration only and are not restrictive. The present application is further described below in conjunction with specific embodiments, but is not intended to limit the scope of the present application.

[0062] definition

[0063] Although various embodiments and aspects of the present application are shown and described herein, it is apparent to those skilled in the art that these embodiments and aspects are provided only as examples. Without departing from the present application, those skilled in the art will now expect many changes, modifications and replacements. It should be understood that various alternatives of the present application embodiments described herein may be adopted when implementing the present application.

[0064] As used herein, the percentage of "identity", such as 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 98.5%, 99%, 99.5% identity, refers to the degree of similarity between amino acid sequences or between nucleotide sequences determined by sequence alignment, which is 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 98.5%, 99%, 99.5%. For example, the proportion of the number of positions with the same base or amino acid residue to the total number of positions determined after two sequences have the same residue at as many positions as possible by introducing spaces, etc. The percentage of "identity" can be determined using software programs known in the art. Preferably, the comparison is performed using default parameters. A preferred comparison program is BLAST. Preferred programs are BLASTN and BLASTP. Details of these programs can be found at the following Internet address: ncbi.nlm.nih.gov / cgi-bin / BLAST.

[0065] As used herein, the "complementarity" of nucleic acids refers to the ability of a nucleic acid to form hydrogen bonds with another nucleic acid through traditional Watson-Crick base pairing. Percent complementarity represents the percentage of residues in a nucleic acid molecule that can form hydrogen bonds (i.e., Watson-Crick base pairing) with another nucleic acid molecule (e.g., about 5, 6, 7, 8, 9, 10 out of 10 are about 50%, 60%, 70%, 80%, 90% and 100% complementary, respectively). "Complete complementarity" refers to the formation of hydrogen bonds between all consecutive residues of a nucleic acid sequence and the same number of consecutive residues in a second nucleic acid sequence. As used herein, "substantially complementary" refers to a degree of complementarity of at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% in a region of about 40, 50, 60, 70, 80, 100, 150, 200, 250 or more nucleotides, or refers to two nucleic acids that hybridize under stringent conditions. For a single base or a single nucleotide, according to the Watson-Crick base pairing principle, when A is paired with T or U, C is paired with G or I, it is called complementary or matching, and vice versa; and other base pairings are called non-complementary. In this application, the "complementary polynucleotide sequence" of a polynucleotide sequence refers to a polynucleotide sequence that is completely complementary to the polynucleotide sequence.

[0066] As used herein, a "conservative substitution variant" of a protein, polypeptide or amino acid sequence refers to one in which one or more amino acid residues undergo amino acid substitution without changing the overall conformation and function of the protein or enzyme, including but not limited to replacing the amino acids in the amino acid sequence of the parent protein in the manner described by the aforementioned "conservative substitution". Therefore, the similarity of two proteins or amino acid sequences with similar functions may be different. For example, a similarity (identity) of 70% to 99% based on the MEGALIGN algorithm. "Conservative substitution variants" also include polypeptides or enzymes with more than 60% amino acid identity as determined by the BLAST or FASTA algorithm, preferably more than 75%, preferably more than 85%, and even more than 90% as the best, and have the same or substantially similar properties or functions compared to the native or parent protein or enzyme.

[0067] As used herein, "coding" refers to i) genetic information contained in a DNA sequence that can be transcribed into an RNA molecule, and / or ii) genetic information contained in an RNA molecule that can be translated into an amino acid sequence. Therefore, as used herein, "coding sequence" can be used to refer to a ribonucleotide (RNA) sequence or a fragment thereof that can be translated into a protein in an mRNA precursor or mature mRNA, and can also refer to a complementary sequence or a fragment thereof of a deoxyribonucleotide (DNA) sequence that is used as a template to transcribe the mRNA precursor or mature mRNA. In addition, the "coding sequence" of the present application may further include polynucleotide sequences encoding proteins, functional nucleic acids, or fragments thereof, such as miRNA, shRNA, dsRNA, guide RNA, Poly (A) tail, 5'UTR, 3'UTR, etc. Among them, a DNA molecule containing genetic information that can be transcribed into an RNA molecule is referred to as the "coding nucleic acid" of the RNA molecule; an RNA molecule containing genetic information that can be translated into an amino acid sequence is referred to as the "coding nucleic acid" of the amino acid sequence.

[0068] As used herein, "MHC" or "MHC complex" refers to the major histocompatibility (MHC) complex molecules typically found on antigen presenting cells. The MHC complex helps, for example, regulate the immune system by presenting antigenic peptides. The MHC complex includes two major classical complexes, MHC-I and MHC-II. The human body's MHC-I complex consists of two human leukocyte antigen (HLA) proteins, referred to in this application as "alpha chain" or "α chain" or "heavy chain" and "beta2m chain" or "β2m chain" or "light chain", which combine to form a heterodimer. The α1 and α2 regions of the α chain are respectively close to and aggregated together to form a peptide binding domain. The α3 region and β2m of the α chain are respectively located closer to the cell membrane and form an immunoglobulin-like domain. The α1 region is located at the N-terminus of the α chain, and the α3 region is located at the C-terminus of the α chain. The α chain and the β chain are usually connected to the cell surface through a transmembrane domain. The human body's MHC-II complex is also composed of two human leukocyte antigen (HLA) proteins, referred to herein as "alpha chain" or "α chain" and "beta chain" or "β chain", which combine to form a heterodimer. The α1 and β1 regions of the α chain and β chain are respectively close and aggregated together to form a peptide binding domain. The α2 and β2 regions of the α chain and β chain are respectively located closer to the cell membrane and form an immunoglobulin-like domain. The N-terminal regions of the α chain and β chain include the α1 and β1 regions, and the C-terminal regions of the α and β chains include the α2 and β2 regions. The α chain and β chain are usually connected to the cell surface through a transmembrane domain.

[0069] As used herein, "human leukocyte antigen" or "HLA" refers to a protein group encoded by the human major histocompatibility complex (MHC) gene complex. The HLA genes encoding the HLA protein group have different alleles, thereby providing different functions for the gene products. HLA proteins belonging to the MHC-I class (e.g., HLA-A, HLA-B, HLA-C) generally present peptides produced from antigens in the cell. The HLA proteins of the MHC-I class include HLA-A, HLA-B, HLA-C, including heterodimeric cell surface receptors of α heavy chain and β2m chain. HLA proteins belonging to the MHC-II class (e.g., HLA-DP, HLA-DQ, HLA-DR) generally present peptides produced from antigens outside the cell. MHC-II class proteins include HLA-DP, HLA-DQ and HLA-DR, including heterodimeric cell surface receptors of α chain and β chain.

[0070] As used herein, "HLA-A heavy chain" or "HLA-A alpha chain" or "HLA-A alpha chain protein" includes any recombinant or naturally occurring form of the human leukocyte antigen (HLA) HLA-A alpha heavy chain protein, also known as MHC-I class A, or a variant or homolog thereof that retains an HLA-A alpha chain protein activity (e.g., at least 50%, 80%, 90%, 95%, 96%, 97%, 98%, 99% or 100% activity compared to an HLA-A alpha chain). In some aspects, the variant or homolog has at least 90%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity over the entire sequence or a portion of the sequence (e.g., a 50, 100, 150 or 200 contiguous amino acid portion) compared to a naturally occurring HLA-A alpha chain polypeptide. In an embodiment, the HLA-A alpha chain is the protein identified by UniProt sequence reference P04439, a homologue or a functional fragment thereof.

[0071] As used herein, "HLA-B heavy chain" or "HLA-B alpha chain" or "HLA-B alpha chain protein" includes any recombinant or naturally occurring form of the human leukocyte antigen (HLA) HLA-B alpha heavy chain protein, also known as MHC-I class B, or variants or homologs thereof that retain HLA-B alpha chain protein activity (e.g., at least 50%, 80%, 90%, 95%, 96%, 97%, 98%, 99% or 100% of the activity compared to HLA-B alpha chain). In some aspects, the variant or homolog has at least 90%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity over the entire sequence or a portion of the sequence (e.g., a 50, 100, 150 or 200 contiguous amino acid portion) compared to a naturally occurring HLA-B alpha chain polypeptide. In an embodiment, the HLA-B alpha chain is the protein identified by UniProt sequence reference P01889, a homologue or a functional fragment thereof.

[0072] As used herein, "HLA-C heavy chain" or "HLA-C alpha chain" or "HLA-C alpha chain protein" includes any recombinant or naturally occurring form of the human leukocyte antigen (HLA) HLA-C alpha heavy chain protein, also known as MHC-I class C, or variants or homologs thereof that retain HLA-C alpha chain protein activity (e.g., at least 50%, 80%, 90%, 95%, 96%, 97%, 98%, 99% or 100% of the activity compared to HLA-C alpha chain). In some aspects, the variant or homolog has at least 90%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity over the entire sequence or a portion of the sequence (e.g., a 50, 100, 150 or 200 contiguous amino acid portion) compared to a naturally occurring HLA-C alpha chain polypeptide. In an embodiment, the HLA-Cα chain is the protein identified by UniProt sequence reference P10321, a homologue or a functional fragment thereof.

[0073] As used herein, "β2m chain" or "β2m chain protein" includes any recombinant or naturally occurring form of the light chain protein component of human leukocyte antigen, β2-microglobulin. In an embodiment, the β2m chain is a protein identified by UniProt sequence reference P61769, a homolog or a functional fragment thereof.

[0074] As used herein, "HLA-DR1, DR4, DR15 alpha chain" or "HLA-DR1, DR4, DR15 alpha chain protein" includes any recombinant or naturally occurring form of the human leukocyte antigen (HLA) HLA-DR alpha chain protein, also known as MHC-II class HLA-DRA, or variants or homologs thereof that retain HLA-DR alpha chain protein activity (e.g., at least 50%, 80%, 90%, 95%, 96%, 97%, 98%, 99% or 100% activity compared to HLA-DRA*01:01). In some aspects, the variant or homolog has at least 90%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity over the entire sequence or a portion of the sequence (e.g., a 50, 100, 150 or 200 consecutive amino acid portion) compared to the naturally occurring HLA-DR4 alpha chain polypeptide. In an embodiment, the HLA-DR alpha chain is the protein identified by UniProt sequence reference P01903, a homologue or a functional fragment thereof.

[0075] As used herein, "HLA-DR β chain" or "HLA-DR β chain protein" includes any recombinant or naturally occurring form of the human leukocyte antigen (HLA) HLA-DR β chain protein, also known as MHC-II class HLA-DRB1*01:01, HLA-DRB1*04:01 or HL-DRB1*15:01, or variants or homologs thereof, which retain HLA-DR1, DR4 or DR15 β chain protein activity (e.g., at least 50%, 80%, 90%, 95%, 96%, 97%, 98%, 99% or within 100% of the activity compared to HLA-DRB1*01:01, HLA-DRB1*04:01 or HL-DRB1*15:01). In some aspects, the variant or homolog has at least 90%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity over the entire sequence or a portion of the sequence (e.g., a 50, 100, 150 or 200 contiguous amino acid portion) compared to a naturally occurring HLA-DR β chain polypeptide. In embodiments, the HLA-DR4 β chain is a protein identified by UniProt sequence reference P13762, a homolog or a functional fragment thereof.

[0076] As used herein, "HLA-DQ6 α chain" or "HLA-DQ6 α chain protein" includes any recombinant or naturally occurring form of the human leukocyte antigen (HLA) DQ α1 chain (HLA-DQ6 α chain), also referred to as DC-1 α chain, DC-α, HLA-DCA, MHC-II class DQA1, or variants or homologs thereof that retain HLA-DQ6 α chain protein activity (e.g., at least 50%, 80%, 90%, 95%, 96%, 97%, 98%, 99% or 100% activity compared to HLA-DQ6 α chain). In some aspects, the variant or homolog has at least 90%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity over the entire sequence or a portion of the sequence (e.g., a 50, 100, 150 or 200 contiguous amino acid portion) compared to a naturally occurring HLA-DQ6 α chain polypeptide. In an embodiment, the HLA-DQ6 alpha chain is the protein identified by UniProt sequence reference P01909, a homolog or a functional fragment thereof.

[0077] As used herein, "HLA-DQ6 beta chain" or "HLA-DQ6 beta chain protein" includes any recombinant or naturally occurring form of human leukocyte antigen (HLA) DRB1 beta chain 1 protein (HLA-DQ6 beta chain), also known as MHC-II class DQB1, HLA-DQB1, or variants or homologs thereof that retain HLA-DQ6 beta chain protein activity (e.g., at least 50%, 80%, 90%, 95%, 96%, 97%, 98%, 99% or 100% of the activity compared to HLA-DQ6 beta chain). In some aspects, the variant or homolog has at least 90%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity over the entire sequence or a portion of the sequence (e.g., a 50, 100, 150 or 200 consecutive amino acid portion) compared to a naturally occurring HLA-DQ6 beta chain polypeptide. In an embodiment, the HLA-DQ6 beta chain is the protein identified by UniProt sequence reference P01920, a homolog or a functional fragment thereof.

[0078] As used herein, "conformational epitope specificity" or "conformational activity" refers to the ability or property of a protein to present a natural three-dimensional structure after correct folding and be recognized and bound by a specified antibody or receptor or binder. It is generally used to describe related antibodies or characteristics that can be detected by these related antibodies. Conformational epitope-specific antibodies are different from linear epitope-specific antibodies. Proteins that can be recognized by conformational epitope-specific antibodies generally retain the structure, function, properties, activity, etc. of natural proteins. However, proteins that can be recognized by linear epitope-specific antibodies cannot directly reflect whether the protein has a natural structure, function, properties, activity, etc.

[0079] For specific proteins described herein, the designated proteins include naturally occurring forms, variants, or homologs of any protein that retain protein transcription factor activity (e.g., at least 50%, 80%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% activity compared to the native protein). In some embodiments, the variant or homolog has at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% amino acid sequence identity over the entire sequence or a portion of the sequence (e.g., 50, 100, 150, or 200 consecutive amino acid portions) compared to the naturally occurring form. In other embodiments, the protein is a protein identified by its NCBI sequence reference. In other embodiments, the protein is a protein identified by its NCBI sequence reference, a homolog thereof, or a functional fragment thereof.

[0080] As used herein, "cell" refers to a cell that performs a metabolic or other function sufficient to preserve or replicate its genomic DNA. Cells can be identified by methods well known in the art, including, for example, the presence of an intact membrane, staining with a specific dye, or the ability to produce progeny. Cells may include prokaryotic and eukaryotic cells. Prokaryotic cells include, but are not limited to, bacteria. Eukaryotic cells include, but are not limited to, yeast cells and cells derived from plants and animals, such as mammals, insects (e.g., fall armyworms), and human cells.

[0081] As used herein, "polynucleotide", "nucleotide sequence" and "nucleic acid molecule" are used interchangeably. They refer to a polymeric form of nucleotides of any length, which may be deoxyribonucleotides or ribonucleotides, or their analogs, and the nucleic acid molecule may be DNA, such as cDNA, genomic DNA or recombinant DNA; the nucleic acid molecule may also be RNA, such as gRNA, mRNA, siRNA, shRNA, sgRNA, miRNA or antisense RNA.

[0082] The term "recombinant" when referring to, for example, a cell, nucleic acid, protein or vector, means that the cell, nucleic acid, protein or vector has been modified by the introduction of a heterologous nucleic acid or protein or an alteration of a native nucleic acid or protein, or that the cell is derived from a cell so modified. For example, a recombinant protein is a protein produced by a recombinant nucleic acid molecule. Nucleic acid molecules can include genetic material from a variety of sources, thereby including non-naturally occurring sequences. Recombinant DNA can be produced by methods known in the art of molecular biology or by synthetic methods. Thus, for example, recombinant cells express genes not found in cells in their natural (non-recombinant) form, or express native genes that are abnormally expressed, under-expressed or not expressed at all. Transgenic cells and plants are those cells and plants that express heterologous genes or coding sequences, usually as a result of recombinant methods.

[0083] As used herein, the term "heterologous" when used to refer to a portion of a nucleic acid means that the nucleic acid comprises two or more subsequences that do not exist in the same relationship to each other in nature. For example, nucleic acids are typically recombinantly produced, having two or more sequences from unrelated genes that are arranged to produce a new functional nucleic acid, such as a promoter from one source and a coding region from another source. Similarly, a heterologous protein means that the protein comprises two or more subsequences that do not exist in the same relationship to each other in nature (e.g., a fusion protein).

[0084] As used herein, the terms "non-naturally occurring" or "engineered" are used interchangeably and refer to human involvement. When these terms are used to describe a nucleic acid molecule or polypeptide, it means that the nucleic acid molecule or polypeptide is at least substantially free of at least one other component with which it is naturally associated or naturally occurring.

[0085] As used herein, an "allele" is a form of a gene or a form of a gene sequence or a form of a protein.

[0086] As used herein, "promoter" refers to a DNA sequence recognized by the cellular synthetic machinery or introduced synthetic machinery required to initiate specific transcription of a polynucleotide sequence.

[0087] As used herein, "signal peptide" refers to an amino acid sequence that is usually present at the N-terminus of a newly synthesized secretory or membrane polypeptide or protein. It acts to direct the polypeptide to a specific cellular location, for example, across the cell membrane, into the cell membrane, or into the nucleus. In some aspects, the signal peptide is removed after localization.

[0088] As used herein, "expression cassette" refers to a nucleic acid molecule comprising a desired coding sequence and a control sequence in operable connection, so that an expression system can use such expression cassette to produce a corresponding expression product, including, for example, an encoded protein or other expression product. The expression cassette includes not only a promoter that initiates transcription of a target gene, but also a signal peptide. Further, the expression cassette may also include a terminator that terminates transcription of the target gene.

[0089] A "non-covalent" or "non-covalent bond" binding or interaction differs from a covalent bond in that it does not involve the sharing of electrons, but rather involves a more diffuse variation of electromagnetic interactions between or within molecules. Non-covalent interactions can be divided into different categories, such as electrostatics, π-effects, van der Waals forces, and hydrophobic effects.

[0090] As used herein, "expression" includes any step involved in the production of polypeptides, including but not limited to transcription, post-transcriptional modification, translation, post-translational modification and secretion. Expression can be detected using conventional techniques for detecting proteins (e.g., ELISA, Western blotting, flow cytometry, immunofluorescence, immunohistochemistry, etc.).

[0091] It should be understood that the present application includes various aspects, embodiments and combinations of the aspects and / or embodiments described herein. The above description and subsequent examples are intended to illustrate rather than limit the scope of the present application. Other aspects, improvements and modifications within the scope of the present application will be apparent to those skilled in the art to which the present application belongs. Therefore, those of ordinary skill in the art should recognize that the scope of the present application also includes the improvements and modifications to the aspects and embodiments.

[0092] cell

[0093] In a first aspect of the present application, a cell is provided, which comprises a human leukocyte antigen molecule (HLA molecule), wherein the HLA molecule comprises a first chain and a second chain, wherein:

[0094] The first chain of the HLA molecule is selected from the HLA-I class heavy chain or the HLA-II class α chain,

[0095] The second chain of the HLA molecule is selected from the light chain of HLA-I class or the beta chain of HLA-II class,

[0096] The first chain and the second chain of the HLA molecule are non-covalently linked to form an HLA molecule having the function of a natural HLA molecule.

[0097] The cells are engineered cells.

[0098] The human leukocyte antigen molecules (HLA molecules) included in the cells described in the present application are recombinant HLA molecules, but the first chain and the second chain of the HLA molecules can form a dimer by non-covalent bonding, and the dimer has the function of a natural HLA molecule.

[0099] The HLA molecules displayed on the cell surface in the present application are the extracellular domains of recombinant HLA molecules, but they can have the functions of natural HLA molecules.

[0100] The HLA-I class molecule displayed on the cell surface in the present application is the extracellular domain of the recombinant HLA-I class molecule, but it can have the function of a natural HLA-I class molecule.

[0101] The HLA-II class molecule displayed on the cell surface in the present application is the extracellular domain of the recombinant HLA-II class molecule, but it can have the function of a natural HLA-II class molecule.

[0102] In the present application, the function of natural HLA molecules refers to the ability to form dimers without artificially connecting molecules. The function of natural HLA molecules also refers to the fact that the dimers formed do not require a connecting peptide to stabilize their dimer structure. The function of natural HLA molecules refers to the ability to form dimers without artificially connecting molecules and the fact that the dimers formed do not require a connecting peptide to stabilize their dimer structure.

[0103] The function of natural HLA-I class molecules refers to the ability to form dimers of heavy chains and light chains without artificially connecting molecules, and the dimers formed can be recognized by conformational epitope-specific antibodies. The function of natural HLA-I class molecules also refers to the fact that the dimers formed do not require a connecting peptide to stabilize their dimer structure, and the presence or absence of a connecting peptide does not affect their ability to be recognized by conformational epitope-specific antibodies. The function of natural HLA-I class molecules refers to the ability to form dimers of heavy chains and light chains without artificially connecting molecules, and the dimers formed can be recognized by conformational epitope-specific antibodies, and the dimers formed do not require a connecting peptide to stabilize their dimer structure, and the presence or absence of a connecting peptide does not affect their ability to be recognized by conformational epitope-specific antibodies.

[0104] The function of natural HLA-II class molecules refers to the ability to form α-chain and β-chain dimers without artificially connecting molecules, and the dimers formed can be recognized by conformational epitope-specific antibodies. The function of natural HLA-II class molecules also refers to the fact that the dimers formed do not require a connecting peptide to stabilize their dimer structure, and the presence or absence of a connecting peptide does not affect their ability to be recognized by conformational epitope-specific antibodies. The function of natural HLA-II class molecules refers to the ability to form α-chain and β-chain dimers without artificially connecting molecules, and the dimers formed can be recognized by conformational epitope-specific antibodies, and the dimers formed do not require a connecting peptide to stabilize their dimer structure, and the presence or absence of a connecting peptide does not affect their ability to be recognized by conformational epitope-specific antibodies.

[0105] In the current prior art, it is difficult to form HLA molecules with natural structure and function by recombinantly expressing human leukocyte antigen molecules (HLA molecules) on the surface of single-cell life systems such as yeast, Escherichia coli, and bacteriophages, only by non-covalent connection or without connecting peptides to stabilize, but the present application has developed a yeast display single-cell system that can recombinantly express HLA molecules with natural structure and function. The single-cell system itself has the characteristics of fast cell breeding, convenient protein expression, and simple research on the function of surface-displayed proteins, which meets the necessary conditions of low cost, high efficiency, and high throughput required for the functional research of multi-allele polymorphic proteins such as HLA and related biomedical development. In addition, human cells expressing HLA molecules almost invariably express multiple HLA alleles, resulting in many current downstream technologies being unable to study the functions of HLA molecules expressed by each HLA allele one by one. Each yeast cell line of the yeast display single-cell system for recombinantly expressing HLA molecules with natural structure and function developed by the present application is a recombinant expression of HLA molecules with natural structure and function corresponding to a single HLA allele, achieving the goal of studying the functions of HLA molecules expressed by each HLA allele one by one.

[0106] When no connecting peptide is required between the dimers to stabilize the dimer structure, the recombinant HLA molecule of the present application has the function of recognizing and / or binding to external antigen peptides, and is applicable to both HLA-I and HLA-II molecules.

[0107] When no connecting peptide is required between the above dimers to stabilize their dimer structure, the recombinant HLA molecule of the present application can further form an HLA-peptide trimer with the T cell epitope peptide. At this time, the trimer can be further recognized by TCR or TCR analogs or TCR derivatives, which is applicable to both HLA-I and HLA-II molecules.

[0108] In some embodiments, the cell is a eukaryotic cell. In some embodiments, the cell is a cell derived from a unicellular organism. In some embodiments, the cell is derived from a unicellular eukaryotic organism. In some embodiments, the cell is a yeast cell. In some embodiments, the yeast is Saccharomyces cerevisiae. In some embodiments, the yeast belongs to strain EBY100 (Boder & Wittrup, 1997).

[0109] In some embodiments, the first chain of the HLA molecule, i.e., the alpha chain of the HLA-I class heavy chain or the HLA-II class, is bound to the surface of the cell by connecting to a molecule on the cell surface. In some embodiments, the molecule can be any molecule that is connected to the first chain of the HLA molecule and bound to the cell surface. In some embodiments, the molecule on the cell surface is bound to the first chain of the HLA molecule by covalent or non-covalent bonds. In some embodiments, the molecule is a protein. In some embodiments, the molecule is a protein, and the first chain of the HLA molecule is bound to the molecule by a peptide bond. In some embodiments, the molecule comprises a structure that can anchor the yeast cell wall. In some embodiments, the molecule comprises a structure that can anchor the yeast cell wall and a secretion signal peptide (or secretion signal region). In some embodiments, the structure that can anchor the yeast cell wall can be directly or indirectly bound to a cell wall glucan or a cell wall mannan. In some embodiments, the structure that can anchor the yeast cell wall can be covalently or non-covalently bound to a cell wall glucan or a cell wall mannan directly or indirectly. In some embodiments, the structure that can anchor the yeast cell wall can be directly or indirectly covalently bound to the cell wall glucan or non-covalently bound to the cell wall mannan. In some embodiments, the structure that can anchor the yeast cell wall and / or the secretion signal peptide are derived from the α-condensin system and / or the flocculin system (glycosylphosphatidylinositol anchor system and flocculin domain anchor system). In some embodiments, the structure that can anchor the yeast cell wall is directly or indirectly combined or connected to the GPI anchor attachment signal region or the flocculation functional region. In some embodiments, the molecule is endogenous to the cell. In some embodiments, the molecule is selected from: Aga2p, α-lectin, α-lectin, flocculin, Cwp1p, Cwp2p or Tip1p. In some embodiments, the protein is Aga2p. In some embodiments, Aga2p is a protein encoded by a gene with GENE ID 852851 in the NCBI database. Aga2p, i.e., Aga2 protein, is a binding subunit of α-condensin, which can bind to the α-condensin core subunit Aga1 protein through a disulfide bond. In some embodiments, Aga2p is a protein encoded by a gene with a GENE ID of 852851 in the NCBI database. In some embodiments, Aga2p has 1, 2, 3, 4, 5, 6 or more mutations in its amino acid sequence compared to a protein encoded by a gene with a GENE ID of 852851 in the NCBI database. In some embodiments, Aga2p does not have an S288C mutation in its amino acid sequence compared to a protein encoded by a gene with a GENE ID of 852851 in the NCBI database.In some embodiments, the amino acid sequence of Aga2p comprises the amino acid sequence as shown in SEQ ID NO: 1, or a conservatively substituted variant of the amino acid sequence as shown in SEQ ID NO: 1, or an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity with the amino acid sequence as shown in SEQ ID NO: 1. In some embodiments, the amino acid sequence of Aga2p is as shown in SEQ ID NO: 1.

[0110] In some embodiments, the first chain and the second chain of the HLA molecule can also form a trimer with a peptide segment. The peptide segment can be an antigenic peptide fragment, such as a tumor-related or specific antigenic peptide fragment. The length of the peptide segment can be 5 to 100 amino acids. For example, the length of the peptide segment can be 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53 , 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100 amino acid peptides. In some embodiments, the length of the peptide segment can be 5 to 50 amino acids. In some embodiments, the length of the peptide segment can be 5 to 20 amino acids. In some embodiments, the peptide segment is an HLA neoantigen peptide, and the trimer formed can recognize and / or bind to a T cell receptor (TCR) or a TCR analog or a TCR derivative.

[0111] In some embodiments, the first chain and the second chain of the HLA molecule are expressed by the cell through two expression cassettes and bound to the cell surface. In some embodiments, the first chain and the second chain of the HLA molecule are expressed in two directions through two different promoters and bound to the cell surface. In some embodiments, the first chain of the HLA molecule is expressed in two directions through the GAL10 promoter, and the second chain is expressed in two directions through the GAL1 promoter and bound to the cell surface. In some embodiments, the first chain of the HLA molecule is expressed in two directions through the GAL1 promoter, and the second chain is expressed in two directions through the GAL10 promoter and bound to the cell surface. After using a dual promoter to express the two chains of the HLA molecule separately, the goal of displaying recombinant HLA molecules with natural structure and function on the surface of eukaryotic single-cell systems such as yeast is achieved. The binding and surface display of the dimer of the recombinant HLA molecule is through non-covalent bonding, and the functional and structural stability does not depend on the connecting peptide, etc.

[0112] In some embodiments, the expression cassette for expressing the first chain and / or the second chain further comprises a signal peptide. In some embodiments, the signal peptide for initiating the expression of the first chain and the second chain of the HLA molecule is SPP SP. In some embodiments, the sequence of the SPP SP is as shown in SEQ ID NO:2. In some embodiments, the signal peptide for initiating the expression of the first chain and the second chain of the HLA molecule is AGA2SP. In some embodiments, the sequence of the AGA2 SP is as shown in SEQ ID NO:3. In some embodiments, the signal peptide for initiating the expression of the first chain of the HLA molecule is SPP SP, and the signal peptide for initiating the expression of the second chain of the HLA molecule is AGA2 SP, the sequence of the SPP SP is as shown in SEQ ID NO:2, and the sequence of the AGA2 SP is as shown in SEQ ID NO:3. In some embodiments, the signal peptide for initiating the expression of the first chain of the HLA molecule is AGA2 SP, and the signal peptide for initiating the expression of the second chain of the HLA molecule is SPP SP, the sequence of the SPP SP is as shown in SEQ ID NO:2, and the sequence of the AGA2 SP is as shown in SEQ ID NO:3. Although the signal peptide SPP SP can guide the extracellular delivery of the two chains of the HLA molecule, the actual expression of the two chains and the surface display level of the HLA dimer are average. The signal peptide AGA2 SP can guide the extracellular delivery of the two chains of the HLA molecule, and the actual expression of the two chains and the surface display level of the HLA dimer are significantly increased.

[0113] In some embodiments, the first chain of the HLA molecule is expressed in two directions through the GAL10 promoter, and the second chain is expressed in two directions through the GAL1 promoter and is bound to the cell surface, and the signal peptide that starts the expression of the first chain and the second chain of the HLA molecule is SPP SP, and the sequence of the SPP SP is shown in SEQ ID NO: 2. In some embodiments, the first chain of the HLA molecule is expressed in two directions through the GAL10 promoter, and the second chain is expressed in two directions through the GAL1 promoter and is bound to the cell surface, and the signal peptide that starts the expression of the first chain and the second chain of the HLA molecule is AGA2 SP, and the sequence of the AGA2 SP is shown in SEQ ID NO: 3. In some embodiments, the first chain of the HLA molecule is expressed in two directions through the GAL10 promoter, and the second chain is expressed in two directions through the GAL1 promoter and is bound to the cell surface, and the signal peptide that starts the expression of the first chain of the HLA molecule is SPP SP, and the signal peptide that starts the expression of the second chain of the HLA molecule is AGA2 SP, and the sequence of the SPP SP is shown in SEQ ID NO: 2, and the sequence of the AGA2 SP is shown in SEQ ID NO: 3. In some embodiments, the first chain of the HLA molecule is expressed in two directions through the GAL10 promoter, and the second chain is expressed through the GAL1 promoter and bound to the cell surface. The signal peptide that initiates the expression of the first chain of the HLA molecule is AGA2 SP, and the signal peptide that initiates the expression of the second chain of the HLA molecule is SPP SP. The sequence of the SPP SP is shown in SEQ ID NO:2, and the sequence of the AGA2 SP is shown in SEQ ID NO:3.

[0114] In some embodiments, the first chain of the HLA molecule is expressed in two directions through the GAL1 promoter, and the second chain is expressed in two directions through the GAL10 promoter and is bound to the cell surface, and the signal peptide that starts the expression of the first chain and the second chain of the HLA molecule is SPP SP, and the sequence of the SPP SP is shown in SEQ ID NO: 2. In some embodiments, the first chain of the HLA molecule is expressed in two directions through the GAL1 promoter, and the second chain is expressed in two directions through the GAL10 promoter and is bound to the cell surface, and the signal peptide that starts the expression of the first chain and the second chain of the HLA molecule is AGA2 SP, and the sequence of the AGA2 SP is shown in SEQ ID NO: 3. In some embodiments, the first chain of the HLA molecule is expressed in two directions through the GAL1 promoter, and the second chain is expressed in two directions through the GAL10 promoter and is bound to the cell surface, and the signal peptide that starts the expression of the first chain of the HLA molecule is SPP SP, and the signal peptide that starts the expression of the second chain of the HLA molecule is AGA2 SP, and the sequence of the SPP SP is shown in SEQ ID NO: 2, and the sequence of the AGA2 SP is shown in SEQ ID NO: 3. In some embodiments, the first chain of the HLA molecule is expressed in two directions through the GAL1 promoter, and the second chain is expressed through the GAL10 promoter and bound to the cell surface. The signal peptide that initiates the expression of the first chain of the HLA molecule is AGA2 SP, and the signal peptide that initiates the expression of the second chain of the HLA molecule is SPP SP. The sequence of the SPP SP is shown in SEQ ID NO:2, and the sequence of the AGA2 SP is shown in SEQ ID NO:3.

[0115] In some embodiments, the first chain is encoded by HLA-A*02:01 or HLA-A*03:01 or HLA-A*11:01 or HLA-A*24:02 or HLA-A*68:02 or other alleles of the HLA-A group, and the second chain is β2m; or the first chain is encoded by HLA-B*07:02 or HLA-B*08:01 or HLA-B*27:05 or HLA-B*35:01 or HLA-B*40:01 or HLA-B*52:01 or other alleles of the HLA-B group, and the second chain is β2m; or the first chain is encoded by HLA-C*01:02 or HLA-C*03:03 or HLA-C*12:03 or other alleles of the HLA-C group, and the second chain is β2m. In some embodiments, the first chain is selected from any one of the amino acid sequences shown in SEQ ID NOs:4-13 or has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity with the amino acid sequence shown in SEQ ID NOs:4-13; or the second chain is the amino acid sequence shown in SEQ ID NO:14 or has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity with the amino acid sequence shown in SEQ ID NO:14.

[0116] In some embodiments, the first chain is encoded by HLA-DRA*01 or other alleles of the HLA-DRA family, and the second chain is encoded by HLA-DRB1*01 or HLA-DRB1*04 or HLA-DRB1*15 or other alleles of the HLA-DRB family; or the first chain is encoded by HLA-DQA1*01 or other alleles of the HLA-DQA1 family, and the second chain is encoded by HLA-DQB1*06 or other alleles of the HLA-DQB1 family; or the first chain is encoded by HLA-DPA1*01:03 or an HLA-DPA1 family allele, and the second chain is encoded by HLA-DPB1*04:01 or an HLA-DPB1 family allele.

[0117] In some embodiments, the first chain is selected from any one of the amino acid sequences shown in SEQ ID NOs: 17 and 21, or has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity with the amino acid sequences shown in SEQ ID NOs: 17 and 21; or the second chain is selected from the amino acid sequence shown in any one of SEQ ID NOs: 18-20 or 22, or has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 18-20 or 22.

[0118] Nucleic Acids

[0119] In the second aspect of the present application, a nucleic acid encoding a human leukocyte antigen molecule (HLA molecule) is provided, wherein the HLA molecule comprises a first chain and a second chain, the first chain of the HLA molecule is selected from the HLA-I class heavy chain or the HLA-II class α chain, the second chain of the HLA molecule is selected from the HLA-I class light chain or the HLA-II class β chain, and the first chain and the second chain of the HLA molecule are non-covalently linked to form an HLA molecule with the function of a natural HLA molecule.

[0120] In some embodiments, the nucleic acid comprises two independent expression cassettes for expressing the first chain and the second chain of the HLA molecule, respectively. In some embodiments, the expression cassette for expressing the first chain comprises a GAL10 promoter, and the expression cassette for expressing the second chain comprises a GAL1 promoter. In some embodiments, the two expression cassettes respectively comprise a nucleic acid sequence for expressing a signal peptide. In some embodiments, the signal peptide is SPP SP or AGA2 SP. In some embodiments, the sequence of the SPP SP is shown in SEQ ID NO:2. In some embodiments, the sequence of the AGA2 SP is shown in SEQ ID NO:3. In some embodiments, the nucleic acid comprises two independent expression cassettes for expressing the first chain and the second chain of the HLA molecule, respectively, the expression cassette for expressing the first chain comprises a GAL10 promoter and a nucleic acid sequence for expressing a signal peptide, and the expression cassette for expressing the second chain comprises a GAL1 promoter and a nucleic acid sequence for expressing a signal peptide, the signal peptide is SPP SP or AGA2 SP, the sequence of the SPP SP is shown in SEQ ID NO:2, and the sequence of the AGA2 SP is shown in SEQ ID NO:3.

[0121] In some embodiments, the nucleic acid is an engineered DNA molecule. In some embodiments, the DNA molecule can be replicated and / or expressed in a cell. In some embodiments, the DNA molecule can be replicated and / or expressed in a eukaryotic cell. In some embodiments, the DNA molecule can be replicated and / or expressed in a prokaryotic cell. In some embodiments, the DNA molecule can be expressed in a eukaryotic cell and can be replicated in a prokaryotic cell. Therefore, the DNA molecule, in addition to comprising a nucleic acid fragment encoding a human leukocyte antigen molecule (HLA molecule), also comprises a gene manipulation or regulatory element for replication and / or expression in a prokaryotic and / or eukaryotic cell.

[0122] The necessary structural elements that make the engineered DNA molecule replicate or efficiently replicate in cells are known in the art, including, for example, an origin of replication (ORI). In some embodiments, the engineered DNA molecule further comprises a marker gene or its fragment and / or a reporter gene or its fragment and a unique restriction endonuclease site that allows insertion of DNA elements, preferably a restriction endonuclease site in the form of a multiple cloning site (MCS). The marker gene is conducive to identifying cells containing a plasmid comprising the marker gene, and can be selected from, for example, an antibiotic resistance gene. Each restriction endonuclease site in the MCS can be specifically recognized by different restriction endonucleases.

[0123] In some embodiments, the DNA molecule is a DNA plasmid. As used herein, the term "DNA plasmid" refers to a plasmid consisting of a double-stranded DNA molecule. In some embodiments, the "plasmid" is a circular DNA molecule. In some embodiments, the "plasmid" can also encompass linear DNA molecules. Specifically, the term "plasmid" also encompasses molecules obtained by, for example, cutting a circular plasmid with a restriction endonuclease, thereby converting the circular plasmid molecule into a linear molecule and linearizing the circular plasmid, and linear molecules that can be replicated in prokaryotes. Plasmids can replicate, i.e., amplify in cells independently of the genomic genetic information stored in the nucleoid or nucleoid of prokaryotes, and can be used for cloning, i.e., for amplifying genetic information in bacterial cells. Preferably, the DNA plasmid according to the present invention is a medium copy or high copy plasmid, more preferably a high copy plasmid. Examples of such high copy plasmids are such vectors: they are based on pUC, pTZ plasmids or any other plasmids (e.g., pMB1, pCoIE1) etc. that contain an ORI that supports high copies of plasmids.

[0124] In some embodiments, the engineered DNA molecule is a DNA molecule or a fragment thereof constituting a nucleoid or a nucleoid of a prokaryotic organism, or a DNA molecule or a fragment thereof constituting a eukaryotic genome, that is, the coding sequence or its complementary sequence comprising the aforementioned HLA can be replicated along with the prokaryotic genome.

[0125] In some embodiments, the engineered DNA molecule can be transcribed into mRNA. In some embodiments, the engineered DNA molecule also comprises a coding sequence of an element that can be used to start or regulate the expression of the protein, polypeptide or its fragment after transcription, and the element includes but is not limited to 5'UTR, 3'UTR, poly (A) tail (or tailing signal), etc. In some embodiments, the engineered DNA molecule comprises a coding sequence of at least one untranslated region (UTR). In some embodiments, the engineered DNA molecule comprises at least the coding sequence of 5'UTR and the coding sequence of the protein, polypeptide or its fragment. In some embodiments, the engineered DNA molecule comprises at least the coding sequence of 5'UTR, the coding sequence of HLA, the coding sequence of 3'UTR, the tailing signal (or the DNA sequence corresponding to the Ploy (A) tail sequence) from 5' to 3', and the start codon (5' end) and the stop codon (3' end) may also be included at both ends of the coding sequence of HLA, which are the first three nucleotides and the last three nucleotides that can be translated of the mRNA molecule, respectively. The 5'UTR usually contains at least one ribosome binding site (RBS), such as the Shine-Dalgarno sequence in prokaryotes, or at least one translation initiation site, such as the Kozak sequence in eukaryotes. The RBS promotes the efficient and accurate translation of mRNA molecules by recruiting ribosomes at the start of translation. Its activity can be optimized by changing the length and sequence of a given RBS or translation revelation site and the distance from the start codon. Alternatively or optionally, the 5'UTR includes an internal ribosome entry site or IRES. The 3'UTR may contain one or more regulatory sequences, such as binding sites for amino acid sequences that enhance the stability of mRNA molecules, binding sites for regulatory RNA molecules (such as miRNA molecules), and / or signal sequences that participate in the intracellular transport of mRNA molecules.

[0126] On the basis of the aforementioned embodiments, in some embodiments, the target gene fragment further comprises one or more additional regulatory sequences, such as binding sites for amino acid sequences that enhance the stability of mRNA molecules, binding sites for amino acid sequences that enhance the translation of mRNA molecules, regulatory elements (such as riboswitches), and / or nucleotide sequences that have a positive impact on translation initiation. In addition, within the 5'UTR, preferably there is no functional upstream open reading frame, an out-of-frame upstream translation initiation site, an out-of-frame upstream start codon, and / or a nucleotide sequence that produces a secondary structure that reduces or prevents translation. The presence of such nucleotide sequences in the 5'UTR can have a negative impact on translation.

[0127] The coding sequence of the HLA comprises codons that can be translated into an amino acid sequence. All the codons contained in the coding sequence may be naturally occurring codons encoding amino acids, or may be partially or entirely composed of artificially synthesized codons. In some embodiments, some or all of the codons are codon-optimized. In some embodiments, some or all of the codons encode non-natural amino acids.

[0128] In some embodiments, the eukaryotic cell is a yeast cell. In some embodiments, the DNA molecule is a yeast display vector.

[0129] In addition, the present application also provides RNA molecules encoding the above HLA molecules. In some embodiments, the RNA molecules are transcribed from the above engineered DNA molecules.

[0130] In some embodiments, the nucleic acid may also be a hybrid molecule of DNA and RNA.

[0131] In some embodiments, the human leukocyte antigen molecule encoded by the nucleic acid is any one of the human leukocyte antigen molecules described above.

[0132] Preparation and identification methods

[0133] The third aspect of the present application provides a method for preparing a human leukocyte antigen molecule (HLA molecule), the method comprising: transforming cells with the nucleic acid molecule of the second aspect above, and culturing the cells under conditions of expressing the human leukocyte antigen molecule (HLA molecule).

[0134] In some embodiments, the cell is a yeast cell, such as a Saccharomyces cerevisiae cell. In some embodiments, the cell is a yeast cell and the nucleic acid is a yeast display vector.

[0135] The fourth aspect of the present application provides a method for identifying HLA neoantigen peptides and vaccines derived therefrom, the method comprising using the human leukocyte antigen molecule involved in the first aspect to recognize and / or bind to the HLA neoantigen peptide.

[0136] The fourth aspect of the present application provides a method for identifying HLA neoantigen receptors, comprising: using the human leukocyte antigen molecule involved in the first aspect to recognize and / or bind to HLA neoantigen peptides; and using the HLA-peptide trimer formed by the human leukocyte antigen molecule involved in the first aspect and the HLA neoantigen peptide to recognize and / or bind to T cell receptor (TCR) or TCR analog or TCR derivative.

[0137] Example

[0138] Example 1 Experimental protocol details

[0139] Unless otherwise specified, materials and reagents used were obtained from commercial sources. Unless otherwise specified, all experimental procedures used were conventional methods.

[0140] Plasmid construction

[0141] To construct a plasmid driving the expression of single-chain trimer pHLA-I (sctHLA-I), the commercially available backbone vector pRS315 was used for plasmid construction and protein expression in yeast. Two pHLA-I complexes were selected in the examples: IDH2 R140Q / HLA-B*07:02 complex and MART1 / HLA-A*02:01 complex. HLA-B*07:02 and HLA-A*02:01 are two common HLA-I heavy chain alleles across different ethnic groups, and these two peptides are derived from tumor-associated antigens, isocitrate dehydrogenase 2 mutant protein (IDH2 R140Q , aa134-143, R140Q mutation: SPNGTIQNIL (SEQ ID NO: 15)) and melanoma antigen recognized by T cells 1 (MART1, aa26-35, A2L mutation: ELAGIGILTV (SEQ ID NO: 16)). The 5' to 3' end of the peptide sequence encoding the syn-pre-pro (SPP) signal peptide (SEQ ID NO: 2), the peptide (IDH2 R140Q The gene expression cassette of the peptide / β2m (SEQ ID NO: 14) / HLA-I heavy chain (SEQ ID NO: 4 or 5) extracellular domain trimer was cloned into the downstream of the GAL10 promoter in pRS315, so that the expressed peptide / β2m / HLA-I heavy chain extracellular domain trimer protein was fused to the N-terminus of the Aga2p yeast native protein subunit, and the C-terminus of pRS315 had an HA epitope tag and MFα terminator. Alternatively, the single-chain trimer was also modified so that the β2m and HLA-I heavy chain were swapped in the gene expression cassette, and the results were as follows. Figure 1 shown.

[0142] The above experimental process was repeated, but the above expression cassette (the genes encoding the SPP signal peptide, peptide / β2m / HLA-I heavy chain extracellular domain trimer from 5' to 3' end) was moved to the C-terminus of Aga2p to evaluate the efficiency of protein fusion at the N-terminus and C-terminus of Aga2p. The resulting plasmid was also constructed using the same backbone vector, and the results are shown in Figure 2 shown.

[0143] Furthermore, in order to construct a plasmid driving the expression of non-covalent heterodimers of pHLA-I, the β2m light chain in the above plasmid was moved to the opposite direction of the bidirectional promoter so that the expression was driven by the GAL1 promoter. That is, the gene expression cassette encoding the SPP signal peptide and the peptide / HLA-I heavy chain extracellular domain from the 5' to the 3' end was cloned into the N-terminus of Aga2p downstream of the GAL10 promoter in pRS315, or the above expression cassette was moved to the C-terminus of Aga2p; the gene expression cassette encoding the SPP signal peptide and β2m from the 3' to the 5' end was cloned into the downstream of the GAL1 promoter in pRS315 and secreted by the same yeast cell receiving the reconstructed plasmid. The results are as follows. Figure 3 To further improve the expression efficiency, the synthetic SPP signal peptide was replaced with the yeast AGA2 signal peptide. AGA2 SP (SEQ ID NO: 3) was initially used to guide the secretion of the natural Aga2p protein subunit. Figure 3 shown.

[0144] In order to construct a plasmid driving the expression of HLA-I non-covalent heterodimers without peptide linkage, the nucleotide sequences encoding the peptides were deleted from the above plasmids. That is, the expression cassettes of the genes encoding the SPP signal peptide and the HLA-I heavy chain extracellular domain from the 5' to the 3' end were cloned into the N-terminus of Aga2p downstream of the GAL10 promoter in pRS315, or the above expression cassettes were moved to the C-terminus of Aga2p; the expression cassettes of the genes encoding the SPP signal peptide and β2m from the 3' to the 5' end were cloned into the downstream of the GAL1 promoter in pRS315 and secreted by the same yeast cells that received the reconstructed plasmids. The results are shown in FIG. Figure 4 To further improve the expression efficiency, the synthetic SPP signal peptide was replaced with the yeast AGA2 signal peptide. Figure 4 shown.

[0145] Adopt and Figure 4 The same experimental protocol was used, but in order to change the HLA-I heavy chain allele without peptide linkage, the extracellular domain of the HLA-I allele, such as HLA-B*07:02, was simply replaced with a given HLA-I allele, i.e., HLA-A*02:01 or HLA-A*03:01 or other alleles. Figure 5 shown.

[0146] Adopt and Figure 4 The same experimental protocol was used, but in order to construct a plasmid driving the expression of HLA-II non-covalent heterodimers without peptide linkage, β2m and HLA-I heavy chain were replaced by the corresponding HLA-II α chain and β chain, respectively. The results are shown in Figure 6 shown.

[0147] Electroporation of yeast cells and expression of HLA

[0148] To construct progeny strains expressing or displaying various HLA protein constructs, the parent yeast strain EBY100 of Saccharomyces cerevisiae was transformed with one constructed yeast vector at a time by electroporation according to the MicroPulser electroporation manual (BioRad). The transformed cells were recovered on selected glucose-based (SD) medium agar plates minus nutrients corresponding to the genes in the pRS315 backbone vector. After culturing at 30°C for 2-3 days, single colonies appeared on the SD agar plates.

[0149] To induce yeast expression of the target protein, a single yeast colony is inoculated into the corresponding liquid SD medium and cultured in a shake tube at 30°C until the exponential growth phase is reached. A sufficient amount of yeast cells is then transferred from the SD medium to the selected galactose-based (SG) medium for protein expression promoted by GAL1 or GAL10. Typically, overnight shaking and induction at 30°C results in efficient expression of the target protein in yeast for flow cytometry detection.

[0150] Immunofluorescence labeling

[0151] To stain yeast cells for flow cytometry, sufficient amount of galactose-induced cells were collected by centrifugation and labeled with primary antibodies in PBS + 1% bovine serum albumin (BSA) for 1 hour on ice. Primary antibodies included HA tag-specific antibodies (Cell signaling), human β2m-specific antibodies (Biolegend), and HLA conformational epitope-specific antibodies, such as mouse monoclonal antibody (mAb) clone W6 / 32 for HLA-I, mAb clone L243 for HLA-DR, mAb clone 40 for HLA-DQ. (BD biosciences). After primary antibody staining, cells were washed at least twice with ice-cold PBS + 1% BSA and labeled with secondary antibodies for 1 h on ice. After secondary antibody staining, cells were washed with ice-cold PBS + 1% BSA and resuspended in PBS + 1% BSA for flow cytometry analysis.

[0152] Flow cytometric analysis

[0153] Flow cytometric data were acquired using a FACSCalibur flow cytometer (BD biosciences). At least 10,000 cell events were collected for each sample and gated by forward and side scatter. FL1 and FL4 fluorescence channels were selected for Alexa FLuor 488 and Alexa FLuor 647, respectively, based on the fluorophores selected in the secondary antibody labeling step above. Data analysis was performed using Flowjo (BD biosciences).

[0154] Embodiment 2:

[0155] Using the single-chain trimer (sct) approach, the HA epitope tag fused to the C-terminus of the expression cassette can be detected on the surface of yeast cells transformed with the sctHLA-I expression plasmid ( Figure 1 This observation is intuitive because, given that Aga1p is a yeast surface protein, the HA tag at the C-terminus of Aga2p should be present on the surface as long as Aga2p and Aga1p form a disulfide bond. We also observed β2m, indicating the presence of sctHLA-I on the surface of these transformed yeast cells. However, using the HLA-I class I protein conformational spatial epitope-specific mAb clone W6 / 32, we detected almost no HLA-I signal compared to background staining ( Figure 1 The absence of conformationally active epitope-active HLA-I molecules suggests that sctHLA-I somehow hinders W6 / 32 recognition of its epitope, raising concerns about the quality of yeast-expressed HLA-I with or without a linker peptide.

[0156] We have ruled out the possibility that the fusion of sctHLA-I to either end of Aga2p would bury the steric epitope on HLA-I for W6 / 32 recognition. The exchange of Aga2p with sctHLA-I resulted in the same absence of conformational steric epitope-active HLA-I fluorescence signal on the surface of the corresponding transformed yeast cells, while the successful detection of HA tag and β2m was not affected ( Figure 2 ). This was independent of peptide or HLA-I allele, as two representative pHLA complexes, IDH2 R140Q No differences were observed between the MART1 / HLA-B*07:02 complex and the MART1 / HLA-A*02:01 complex ( Figure 1 and Figure 2 ). Therefore, the sctHLA-I construct itself may have a negative impact on the recognition of W6 / 32.

[0157] Since W6 / 32 recognizes native HLA proteins composed of two polypeptide chains that are mostly expressed independently and bound to each other by noncovalent bonds, it is theoretically possible to display HLA in a noncovalent heterodimeric form on the surface of yeast cells. To achieve this goal in the new yeast plasmid set, β2m and a peptide-linked HLA-I heavy chain (e.g., IDH2 R140Q / HLA B*07:02) were driven by GAL1 and GAL10 from the bidirectional GAL1-10 promoter, respectively, in which the heavy chain was fused to the N-terminus of Aga2p, followed by the HA tag. This key modification enabled flow cytometry to successfully detect a clear HLA-I positive population (which had never been observed before) compared to the background fluorescence signal. Figure 3 ). This conformational spatial epitope-active HLA-I signal corresponding to W6 / 32 staining was significantly enhanced after SPP SP was replaced by the yeast native signal peptide AGA2 SP. Notably, fusion of peptide-linked HLA-I heavy chain to either the N-terminus or the C-terminus of AGA2p had negligible effect on the enhancement of HLA-I signal attributed to AGA2 SP replacement.

[0158] Embodiment 3:

[0159] The original idea of ​​using the sctHLA-I approach was to increase the chances of dimerization between β2m and heavy chain, while applying a linker peptide to stabilize the β2m / heavy chain heterodimer. It is clear that the non-covalent dimer construct of the EXTREME system showed superior properties compared to the sctHLA-I in the yeast display system, especially in terms of staining of the conformational spatial epitope-specific antibody W6 / 32. Here, we further evaluated the advantages of our construct in the absence of a peptide. After removing the linker peptide at the N-terminus of the heavy chain, the peptide-free version of the non-covalent HLA-I heterodimer displayed by the corresponding yeast strain ( Figure 4 ) showed a W6 / 32 signal intensity higher than that of the peptide-linked HLA-I heterodimer displayed by the yeast strains above ( Figure 3 ) with a moderate decrease in the corresponding signal intensity. We noted that in the absence of peptide, the HLA-B*07:02 / β2m heterodimer signal was attenuated more when fused to the C-terminus of Aga2p. In addition to the overall β2m signal attenuation, a decrease in the signal of β2m staining of the corresponding strain was observed compared to the sctHLA-I approach ( Figure 3 , Figure 4 and Figure 2 ). We believe this is a result of partial burial of the β2m antibody epitope and may be attributed to the correct folding of the HLA-B*07:02 / β2m heterodimer. Importantly, we have created for the first time an EXTREME system for yeast display of HLA-I proteins recognized by the conformational epitope-specific mAb W6 / 32, whose conformational activity, protein function, and stability after dimerization are largely independent of the presence of the peptide.

[0160] Embodiment 4:

[0161] To demonstrate the broad utility of our EXTREME platform for displaying a variety of HLA-I alleles, we selectively expressed nine other HLA-I heavy chain alleles as well as independently expressed β2m. The nine HLA-I alleles include HLA-A*02:01 (SEQ ID NO:5), HLA-A*03:01 (SEQ ID NO:6), HLA-A*11:01 (SEQ ID NO:7), HLA-A*24:02 (SEQ ID NO:8), HLA-B*27:05 (SEQ ID NO:9), HLA-B*35:01 (SEQ ID NO:10), HLA-B*40:01 (SEQ ID NO:11), HLA-C*03:03 (SEQ ID NO:12), HLA-C*12:03 (SEQ ID NO:13), and HLA-A*24:02 (SEQ ID NO:8). All nine yeast strains transformed with the corresponding HLA-I encoding plasmids successfully displayed HLA-I molecules recognizable by the conformational epitope-specific mAb W6 / 32 and also showed positive fluorescent signals representing β2m-specific antibody staining ( Figure 5 and Figure 6 ). The level of surface display indicated by the fluorescent signal of HLA-I or β2m varied depending on the allele selected. To confirm that display was via a protein fusion between the HLA-I heterodimer and Aga2p, we deleted Aga2p from the plasmid driving expression of the peptide-linked HLA-B*07:02 / β2m heterodimer and transformed yeast with the resulting plasmid. As expected, in the absence of the Aga2p fusion, the W6 / 32 or β2m fluorescent signal ( Figure 4 ) disappears completely ( Figure 5 ).

[0162] Embodiment 5:

[0163] The EXTREME platform was also used to display HLA-II alleles with promising results. We used yeast cells transformed with plasmids driving independent expression of the HLA-II DR or DQ α and β chains of the corresponding allele protein extracellular domains to display the conformational epitope-specific mAbs L243 or Recognizable HLA-II molecules ( Figure 6These HLA-II proteins include DR1 (HLA-DRA*01:01 (SEQ ID NO:17) / HLA-DRB1*01:01 (SEQ ID NO:18)), DR4 (HLA-DRA*01:01 (SEQ ID NO:17) / HLA-DRB1*04:01 (SEQ ID NO:19)), DR15 (HLA-DRA*01:01 (SEQ ID NO:17) / HLA-DRB1*15:01 (SEQ ID NO:20)), and DQ6 (HLA-DQA1*01:02 (SEQ ID NO:21) / HLA-DRB1*06:02 (SEQ ID NO:22)). On the yeast surface, we observed different peptide-free HLA-II non-covalent heterodimers, and also noticed significant variations in HLA-II conformational spatial epitope-specific mAb staining between different HLA-II alleles ( Figure 7 ).

[0164] Sequence Listing

[0165]

[0166]

[0167]

Claims

1. A cell comprising a human leukocyte antigen molecule (HLA molecule), wherein the HLA molecule comprises a first chain and a second chain, in, The first chain of the HLA molecule is selected from the HLA-I class heavy chain or the HLA-II class α chain, The second chain of the HLA molecule is selected from the light chain of HLA-I class or the beta chain of HLA-II class, The first chain and the second chain of the HLA molecule are non-covalently linked to form an HLA molecule having the function of a natural HLA molecule.

2. The cell of claim 1, wherein the cell is a yeast cell.

3. The cell according to claim 1 or 2, wherein the first chain of the HLA molecule is linked to a molecule on the surface of the cell and binds to the surface of the cell.

4. The cell of claim 3, wherein the molecule is a protein.

5. The cell of claim 4, wherein the protein is endogenous to the cell.

6. The cell of claim 4, wherein the protein is Aga2p, a-lectin, α-lectin, flocculin, Cwp1p, Cwp2p or Tip1p.

7. The cell of claim 4, wherein the protein is Aga2p. The cell according to claim 7 , wherein the amino acid sequence of Aga2p is as shown in SEQ ID NO:

1.

9. The cell according to any one of claims 1 to 8, wherein the first chain and the second chain of the HLA molecule form a trimer with the peptide segment.

10. The cell according to any one of claims 1 to 9, wherein the first chain and the second chain of the HLA molecule are expressed by the cell via two expression cassettes, respectively, and are bound to the cell surface.

Citation Information

Patent Citations

  • Novel peptides and scaffolds for use in immunotherapy against head and neck squamous cell carcinoma and other cancers

    CN109803981A

  • Recombinant vector for enhancing ability of displaying Fab fragment antigen binding on yeast cell surface by using endoplasmic reticulum retrieval signal sequence

    CN110218737A

  • Improved antigen binding receptor formats

    CN110461360A

  • Oral vaccines expressed in yeast for covid-19

    CN113528564A

  • Cross reactive epitopes for multiple sclerosis

    CN115315440A